CX3CL1 与 CX3CR1 在乳腺非特殊类型浸润性癌中的表达及其临床意义
| 作者: |
1孟媛,
1许斌
1 抚顺市中心医院病理科，辽宁 抚顺 113006 |
| 通讯: |
许斌
Email: 646922136@qq.com |
| DOI: | 10.3978/j.issn.2095-6959.2019.04.010 |
摘要
目的：研究乳腺非特殊类型浸润性癌中趋化因子CX3CL1及其受体CX3CR1的表达，分析CX3CL1和CX3CR1表达与乳腺非特殊类型浸润性癌的临床病理学特征、分子亚型、激素受体的关系。方法：80例乳腺非特殊类型浸润性癌中，应用免疫组织化学法观察CX3CL1，CX3CR1的表达情况，然后进一步探讨乳腺非特殊类型浸润性癌中CX3CL1与CX3CR1单一表达或共同表达时，与临床病理因素的关联。结果：乳腺非特殊类型浸润性癌中CX3CL1和CX3CR1阳性表达率均与肿瘤临床分期相关(P<0.05)；乳腺非特殊类型浸润性癌中CX3CL1与CX3CR1共同表达时，阳性率与肿瘤临床分期、淋巴结转移、非Luminal A分子分型以及患者较差的5年生存率相关(P<0.05)。结论：CX3CL1与CX3CR1在乳腺非特殊类型浸润性癌中同时阳性表达与患者较高肿瘤临床分期、淋巴结转移及较差的5年生存率相关。在乳腺非特殊类型浸润性癌中同时检测CX3CL1与CX3CR1表达，比单独检测CX3CL1或CX3CR1分子标志更具有临床意义。
关键词：
乳腺非特殊类型浸润性癌；CX3CL1；CX3CR1；临床病理特征
Expression and clinical significance of CX3CL1 and CX3CR1 in non-specific invasive breast carcinoma
CorrespondingAuthor: XU Bin Email: 646922136@qq.com
DOI: 10.3978/j.issn.2095-6959.2019.04.010
Abstract
Objective: To discuss the expression of the chemokine CX3CL1 and its receptor CX3CR1 in non-specific invasive breast carcinoma, and to analyze the relationship between the expression of CX3CL1 and CX3CR1, and the clinicopathological characteristics, molecular subtypes and hormone receptors of non-specific invasive breast cancer. Methods: The expression of CX3CL1 and its receptor CX3CR1 were investigated in 80 invasive ductal breast cancer by immunohistochemistry. The relation of CX3CL1 and its receptor CX3CR1 expression or co-expression and clinichistological characteristics, molecular subtype, biomarker was analyzed. Results: CX3CL1 and CX3CR1 positive expression are both correlated with tumor clinical stage (P<0.05). The results of immunohistochemistry demonstrated CX3CL1 and CX3CR1 co-expression is correlated tumor clinical stage with lymphatic metastasis in non-specific invasive breast carcinoma (P<0.05). CX3CL1 and CX3CR1 co-expression is linked to poor outcome in breast cancer patients. Conclusion: Co-expression of CX3CL1 and CX3CR1 could be correlated with poor outcome in non-specific invasive breast carcinoma.
Keywords：
non-specific invasive breast carcinoma; CX3CL1; CX3CR1; clinicopathological characteristics